Is it justifiable to withhold treatment for hepatitis C from illicit-drug users?
作者信息
Edlin B R, Seal K H, Lorvick J, Kral A H, Ciccarone D H, Moore L D, Lo B
机构信息
Urban Health Study, Institute for Health Policy Studies, University of California, San Francisco 94110, USA.
出版信息
N Engl J Med. 2001 Jul 19;345(3):211-5. doi: 10.1056/NEJM200107193450311.
Abstract
摘要
相似文献
1
Is it justifiable to withhold treatment for hepatitis C from illicit-drug users?
N Engl J Med. 2001 Jul 19;345(3):211-5. doi: 10.1056/NEJM200107193450311.
2
Treatment of chronic hepatitis C in active drug users.
N Engl J Med. 2001 Jul 19;345(3):215-7. doi: 10.1056/NEJM200107193450312.
3
[Treatment of hepatitis C in intravenous drug users].
Gastroenterol Clin Biol. 2002 Apr;26 Spec No 2:B252-6.
4
Elimination on the agenda for hepatitis C.
Lancet Infect Dis. 2014 Jun;14(6):452-3. doi: 10.1016/s1473-3099(14)70704-2.
5
[Hepatitis C and drug use: epidemiology, screening, natural history and treatment].
Gastroenterol Clin Biol. 2002 Apr;26 Spec No 2:B112-20.
6
Enhancing hepatitis C treatment uptake and outcomes for injection drug users.
Hepatology. 2007 Jan;45(1):3-5. doi: 10.1002/hep.21478.
7
The drugs that dare not speak their name: Injecting and other illicit drug use during treatment for hepatitis C infection.
Int J Drug Policy. 2007 Oct;18(5):374-80. doi: 10.1016/j.drugpo.2006.12.018. Epub 2007 Jan 23.
8
Initiation of methamphetamine abuse during interferon treatment.
Am J Psychiatry. 2007 Sep;164(9):1439. doi: 10.1176/appi.ajp.2007.06122083.
9
Is treatment failure for hepatitis C virus infection in HIV-positive drug users associated with a shift in HCV genotypes?
J Acquir Immune Defic Syndr. 2003 Apr 1;32(4):465-6. doi: 10.1097/00126334-200304010-00020.
10
Newly acquired hepatitis C--many hurdles from diagnosis until treatment initiation.
J Gastroenterol Hepatol. 2008 Dec;23(12):1782-4. doi: 10.1111/j.1440-1746.2008.05698.x.
引用本文的文献
1
Hepatitis Risk in Diabetes Compared to Non-Diabetes and Relevant Factors: A Cross-Sectional Study with National Health and Nutrition Examination Survey (NHANES), 2013-2018.
Int J Environ Res Public Health. 2023 Mar 11;20(6):4962. doi: 10.3390/ijerph20064962.
2
Debating Medical Utility, Not Futility: Ethical Dilemmas in Treating Critically Ill People Who Use Injection Drugs.
J Law Med Ethics. 2018 Jun;46(2):241-251. doi: 10.1177/1073110518782925.
3
A Guide to the Economics of Hepatitis C Virus Cure in 2017.
Infect Dis Clin North Am. 2018 Jun;32(2):447-459. doi: 10.1016/j.idc.2018.02.013.
4
Treatment of Chronic Hepatitis C in Patients Receiving Opioid Agonist Therapy: A Review of Best Practice.
Infect Dis Clin North Am. 2018 Jun;32(2):347-370. doi: 10.1016/j.idc.2018.02.001.
5
Perceived benefits of the hepatitis C peer educators: a qualitative investigation.
Harm Reduct J. 2017 Sep 29;14(1):67. doi: 10.1186/s12954-017-0192-8.
6
Efficacy of peginterferon plus ribavirin in patients receiving opioid substitution therapy : Final results of the Austrian PegHope study.
Wien Klin Wochenschr. 2018 Jan;130(1-2):54-61. doi: 10.1007/s00508-017-1263-2. Epub 2017 Sep 12.
7
Retention in buprenorphine treatment is associated with improved HCV care outcomes.
J Subst Abuse Treat. 2017 Apr;75:38-42. doi: 10.1016/j.jsat.2017.01.015. Epub 2017 Jan 27.
8
High hepatitis C virus prevalence among drug users in Iran: systematic review and meta-analysis of epidemiological evidence (2001-2012).
Int J Infect Dis. 2015 Nov;40:116-30. doi: 10.1016/j.ijid.2015.09.022. Epub 2015 Oct 13.
9
Successful treatment of chronic hepatitis C with triple therapy in an opioid agonist treatment program.
Int J Drug Policy. 2015 Oct;26(10):1014-9. doi: 10.1016/j.drugpo.2015.08.008. Epub 2015 Aug 20.
10
Excluding people who use drugs or alcohol from access to hepatitis C treatments – Is this fair, given the available data?
J Hepatol. 2015 Oct;63(4):779-82. doi: 10.1016/j.jhep.2015.06.014. Epub 2015 Aug 4.
本文引用的文献
1
Prevalence and duration of hepatitis C among injection drug users in San Francisco, Calif.
Am J Public Health. 2001 Jan;91(1):46-7. doi: 10.2105/ajph.91.1.46.
2
Sharing of drug preparation equipment as a risk factor for hepatitis C.
Am J Public Health. 2001 Jan;91(1):42-6. doi: 10.2105/ajph.91.1.42.
3
Peginterferon alfa-2a in patients with chronic hepatitis C.
N Engl J Med. 2000 Dec 7;343(23):1666-72. doi: 10.1056/NEJM200012073432301.
4
Physician prescribing of sterile injection equipment to prevent HIV infection: time for action.
Ann Intern Med. 2000 Aug 1;133(3):218-26. doi: 10.7326/0003-4819-133-3-200008010-00015.
5
Neuropsychiatric symptoms associated with hepatitis C and interferon alpha: A review.
Am J Psychiatry. 2000 Jun;157(6):867-76. doi: 10.1176/appi.ajp.157.6.867.
6
Helping the urban poor stay with antiretroviral HIV drug therapy.
Am J Public Health. 2000 May;90(5):699-701. doi: 10.2105/ajph.90.5.699.
7
The effect of syringe exchange use on high-risk injection drug users: a cohort study.
AIDS. 2000 Mar 31;14(5):605-11. doi: 10.1097/00002030-200003310-00015.
8
Adherence to HAART in French HIV-infected injecting drug users: the contribution of buprenorphine drug maintenance treatment. The Manif 2000 study group.
AIDS. 2000 Jan 28;14(2):151-5. doi: 10.1097/00002030-200001280-00010.
9
Pathogenesis, natural history, treatment, and prevention of hepatitis C.
Ann Intern Med. 2000 Feb 15;132(4):296-305. doi: 10.7326/0003-4819-132-4-200002150-00008.
10
Epidemiology of hepatitis C in the United States.
Am J Med. 1999 Dec 27;107(6B):2S-9S. doi: 10.1016/s0002-9343(99)00373-3.
Zotero 插件